Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
Objective: To describe the frequency and spectrum of treatment-related adverse events (TRAEs) of immunotherapy combined with antiangiogenic therapy in patients with melanoma.Methods: This retrospective cohort study included three clinical trials on patients with stage III/IV melanoma treated with an...
Guardado en:
Autores principales: | Hui Tian, Xuan Wang, Bin Lian, Xieqiao Yan, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Siming Li, Li Zhou, Chuanliang Cui, Jun Guo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/263504d5f99249bc929eaada676564f3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Rui Xing, et al.
Publicado: (2021) -
Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021) -
Composition of Algerian Propolis, Plant Origin, and Its Antiangiogenic Activity In Vitro
por: Takahiro Hosoya, et al.
Publicado: (2021) -
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
por: Clavreul A, et al.
Publicado: (2019) -
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
por: Vincenzo De Falco, et al.
Publicado: (2021)